American International Group Inc. Sells 445 Shares of Progyny, Inc. (NASDAQ:PGNY)

Share on StockTwits

American International Group Inc. decreased its position in Progyny, Inc. (NASDAQ:PGNY) by 2.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,523 shares of the company’s stock after selling 445 shares during the period. American International Group Inc.’s holdings in Progyny were worth $658,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in PGNY. US Bancorp DE acquired a new stake in shares of Progyny during the 4th quarter worth approximately $30,000. Parallel Advisors LLC boosted its stake in Progyny by 89.5% during the fourth quarter. Parallel Advisors LLC now owns 978 shares of the company’s stock worth $41,000 after buying an additional 462 shares in the last quarter. Capstone Triton Financial Group LLC acquired a new stake in Progyny during the fourth quarter worth $47,000. Harvard Management Co. Inc. bought a new stake in Progyny in the 4th quarter valued at $159,000. Finally, Victory Capital Management Inc. acquired a new position in shares of Progyny in the 3rd quarter valued at $201,000. Institutional investors own 58.54% of the company’s stock.

NASDAQ PGNY opened at $44.87 on Thursday. Progyny, Inc. has a 1-year low of $17.90 and a 1-year high of $53.48. The company has a 50 day moving average of $46.21 and a 200-day moving average of $39.10. The firm has a market cap of $3.91 billion, a price-to-earnings ratio of 407.91 and a beta of 1.83.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Wednesday, February 24th. The company reported $0.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.01. The firm had revenue of $100.30 million during the quarter. Progyny had a return on equity of 7.43% and a net margin of 1.03%. Research analysts expect that Progyny, Inc. will post 0.14 earnings per share for the current year.

Several research analysts recently issued reports on PGNY shares. Bank of America raised shares of Progyny from a “neutral” rating to a “buy” rating in a research report on Tuesday, March 16th. Zacks Investment Research downgraded Progyny from a “hold” rating to a “sell” rating in a research report on Saturday, February 27th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $37.71.

In other Progyny news, COO Peter Anevski sold 21,000 shares of the stock in a transaction on Monday, February 1st. The stock was sold at an average price of $47.93, for a total value of $1,006,530.00. Following the transaction, the chief operating officer now directly owns 666,146 shares in the company, valued at approximately $31,928,377.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David J. Schlanger sold 112,020 shares of Progyny stock in a transaction on Tuesday, April 6th. The shares were sold at an average price of $46.10, for a total value of $5,164,122.00. Insiders sold 421,263 shares of company stock valued at $19,823,422 over the last ninety days. 33.30% of the stock is currently owned by company insiders.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

See Also: Equity Income

Want to see what other hedge funds are holding PGNY? Visit to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY).

Institutional Ownership by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with's FREE daily email newsletter.